Loading...
XNAS
ORMP
Market cap175mUSD
Jul 09, Last price  
4.18USD
1D
-2.56%
1Q
18.41%
Jan 2017
-31.70%
IPO
-65.17%
Name

Oramed Pharmaceuticals Inc

Chart & Performance

D1W1MN
XNAS:ORMP chart
P/E
2.67
P/S
85.54
EPS
1.57
Div Yield, %
—
Shrs. gr., 5y
15.62%
Rev. gr., 5y
-5.90%
Revenues
2m
00000197,412184,254000641,0002,456,0002,449,0002,703,0002,710,0002,703,0002,703,0001,340,00002,000,000
Net income
64m
P
-414,576-3,236,000-2,769,271-2,760,474-2,977,376-1,561,245-3,344,478-4,231,812-5,696,000-7,232,000-10,964,000-10,480,000-12,727,000-14,355,000-11,511,000-22,238,000-37,764,0005,525,000-19,103,00064,050,000
CFO
-9m
L+8.71%
-361,613-611,000-1,836,958-2,252,923-1,418,464-1,666,045-2,301,608-3,395,341-4,067,999-4,946,0004,655,000-5,831,000-14,657,000-12,940,000-12,440,000-21,181,000-28,701,000-10,295,000-8,412,000-9,145,000
Dividend
Jan 16, 20260.25 USD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins. It develops ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes. The company has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York, New York.
URL
https://oramed.com/
IPO date
Apr 01, 2002
Employees
13
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑082020‑082019‑082018‑082017‑082016‑08
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT